Sobi’s Aspaveli (pegcetacoplan) Receives NICE Recommendation for the Treatment of Paroxysmal Nocturnal Haemoglobinuria
Shots:
- NICE has issued a positive FAD which recommends the use of Aspaveli as a treatment option in adults with PNH who are anemic after treatment with a C5 inhibitor in England & Wales
- The recommendation is based on the P-III (PEGASUS) study to evaluate pegcetacoplan vs eculizumab in 80 adults with PNH which showed an improvement in hemoglobin levels & FACIT fatigue scores, reduction in transfusion requirements
- Aspaveli is currently undergoing assessment with the MHRA for marketing authorization in the UK. Sobi & Apellis collaborated to co-develop pegcetacoplan where Sobi gets exclusive ex-US commercialisation rights & Apellis gets US commercialization rights for systemic pegcetacoplan
Ref: PharmiWeb | Image: Sobi
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com